<p>RxSight (NASDAQ:RXST - 獲得免費報告) 於週一發佈了其財報。公司報告稱，該季度每股收益為（-0.16）美元，低於分析師預期的（-0.07）美元，Briefing.com 報道。該季度公司營收為 3,489 萬美元，而分析師預期為 3,233 萬美元。RxSight 的淨資產收益率為-27.68%，淨利潤率為-44.01%。公司營收同比增長了 67.6%。在去年同期，公司每股收益為（-0.40）美元。</p>
<h2>RxSight 股價上漲 16.5%</h2>
<p>週二，納斯達克 RXST 股價上漲 6.72 美元，達到 47.50 美元。公司股票交易量為 668,371 股，高於平均交易量 485,248 股。RxSight 的 52 周最低價為 20.66 美元，52 周最高價為 66.54 美元。公司市值為 17.6 億美元，市盈率為-39.68，貝塔係數為 1.19。公司的 50 天移動平均價格為 53.44 美元，200 天移動平均價格為 53.43 美元。</p>
<h2>分析師評級變動</h2>
<p>近期有多位分析師對該公司發表了看法。Needham &amp; Company LLC 將 RxSight 的目標股價從 75.00 美元降至 54.00 美元，並在週二的研究報告中為該公司設定了 “買入” 評級。BTIG Research 將 RxSight 的價格目標從 72.00 美元上調至 73.00 美元，並在 7 月 15 日星期一的研究報告中為該公司設定了 “買入” 評級。Oppenheimer 將 RxSight 的目標股價從 72.00 美元降至 65.00 美元，並在週二的研究報告中為該股設定了 “表現優異” 評級。Stifel Nicolaus 將 RxSight 的目標股價從 70.00 美元降至 65.00 美元，並在週二的研究報告中為該公司設定了 “買入” 評級。最後，富國銀行將 RxSight 的目標股價從 68.00 美元降至 54.00 美元，並在週二的研究報告中為該股設定了 “超重” 評級。根據 MarketBeat 的數據，共有七位分析師對該股票給予買入評級，目前市場普遍看好該公司，預期目標股價為 58.43 美元。</p>
<p><strong>閲讀我們關於 RXST 的最新股票報告</strong></p>
<h2>內部人士的交易</h2>
<p>在其他 RxSight 新聞中，董事朱莉·安德魯斯於 6 月 14 日星期五以每股 58.00 美元的均價出售了 15,625 股股票。交易總額為 906,250.00 美元。交易完成後，該董事在公司中直接持有 30,287 股股票，價值 1,756,646 美元。該交易已在證券交易委員會的一份文件中披露，可通過此超鏈接訪問。此外，RxSight 的另一條消息顯示，首席財務官雪莉·B·圖南於 7 月 1 日星期一以每股 58.61 美元的均價出售了 10,000 股 RxSight 股票。交易總額為 586,100.00 美元。交易完成後，首席財務官現在持有公司 13,938 股股票，價值約 816,906.18 美元。有關此交易的披露可在此處找到。公司內部人士持有公司股份的比例為 9.36%。</p>
<h2>關於 RxSight（獲得免費報告）</h2>
<p>RxSight, Inc.是一家商業化階段的醫療器械公司，從事研究、開發、製造和銷售用於白內障手術的可調光人工晶狀體（LAL）在美國和國際市場的使用。公司提供的 RxSight 系統使醫生能夠為白內障手術後的患者定製和增強視力。</p>
<h2>精選文章</h2>
<ul>
<li>我們喜歡的五隻股票勝過 RxSight</li>
<li>什麼是股息成就者？簡介</li>
<li>Uber 的盈利超預期：共享乘車和外賣激增</li>
<li>紐約證券交易所股票為投資者提供多樣的優質選擇</li>
<li>Hims &amp; Hers 報告季度業績強勁：股價即將上漲</li>
<li>解析科技股：瞭解科技股的相關知識</li>
<li>Cloudflare 股價因業績超預期和業績指引上調而飆升</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlhTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlhTVA"/></p>
<p><em>此即時新聞警報由 MarketBeat 的敍事科技和金融數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊的審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ 時間不多了-6 月 25 日截止日期即將到來！（來自 Paradigm Press）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDEz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDEz"/></p>
<h2>現在是否值得投資 1,000 美元購買 RxSight？</h2>
<p>在考慮 RxSight 之前，您需要聽到這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂尖和表現最佳的研究分析師以及他們向客户推薦的股票。MarketBeat 已確定了頂級分析師悄悄告訴客户在更廣泛市場注意之前購買的五隻股票...而 RxSight 並不在名單上。</p>
<p>儘管 RxSight 目前在分析師中有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

RXST

<p>RxSight（NASDAQ:RXST）報告的季度每股收益為（$0.16），低於預期（$0.09）。該公司營收為 3.489 億美元，超過分析師的預期。RxSight 的營收同比增長了 67.6%。週二，該股上漲了 16.5%。多位分析師對該股票給予 “買入” 評級。內部人士一直在拋售該公司的股票。RxSight 是一家專門從事可調節光學人工晶狀體的醫療器械公司</p>

<p>RxSight (NASDAQ:RXST - Get Free Report) released its earnings results on Monday. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.09), Briefing.com reports. The firm had revenue of $34.89 million for the quarter, compared to analyst estimates of $32.33 million. RxSight had a negative return on equity of 27.68% and a negative net margin of 44.01%. The firm's revenue was up 67.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.40) EPS.</p>
<div class="lb-trans"><p>RxSight (NASDAQ:RXST - 獲得免費報告) 於週一發佈了其財報。公司報告稱，該季度每股收益為（-0.16）美元，低於分析師預期的（-0.07）美元，Briefing.com 報道。該季度公司營收為 3,489 萬美元，而分析師預期為 3,233 萬美元。RxSight 的淨資產收益率為-27.68%，淨利潤率為-44.01%。公司營收同比增長了 67.6%。在去年同期，公司每股收益為（-0.40）美元。</p>
</div><h2>RxSight Trading Up 16.5 %</h2>
<div class="lb-trans"><h2>RxSight 股價上漲 16.5%</h2>
</div><p>NASDAQ RXST traded up $6.72 on Tuesday, reaching $47.50. The company's stock had a trading volume of 668,371 shares, compared to its average volume of 485,248. RxSight has a 52 week low of $20.66 and a 52 week high of $66.54. The firm has a market cap of $1.76 billion, a PE ratio of -39.68 and a beta of 1.19. The business has a 50-day moving average price of $53.44 and a 200 day moving average price of $53.43.</p>
<div class="lb-trans"><p>週二，納斯達克 RXST 股價上漲 6.72 美元，達到 47.50 美元。公司股票交易量為 668,371 股，高於平均交易量 485,248 股。RxSight 的 52 周最低價為 20.66 美元，52 周最高價為 66.54 美元。公司市值為 17.6 億美元，市盈率為-39.68，貝塔係數為 1.19。公司的 50 天移動平均價格為 53.44 美元，200 天移動平均價格為 53.43 美元。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>Several analysts recently weighed in on the company. Needham &amp; Company LLC decreased their target price on RxSight from $75.00 to $54.00 and set a &#34;buy&#34; rating for the company in a research note on Tuesday. BTIG Research increased their price objective on RxSight from $72.00 to $73.00 and gave the company a &#34;buy&#34; rating in a research report on Monday, July 15th. Oppenheimer lowered their price objective on shares of RxSight from $72.00 to $65.00 and set an &#34;outperform&#34; rating on the stock in a research note on Tuesday. Stifel Nicolaus cut their target price on shares of RxSight from $70.00 to $65.00 and set a &#34;buy&#34; rating for the company in a research note on Tuesday. Finally, Wells Fargo &amp; Company decreased their price target on shares of RxSight from $68.00 to $54.00 and set an &#34;overweight&#34; rating on the stock in a research report on Tuesday. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of &#34;Buy&#34; and a consensus target price of $58.43.</p>
<div class="lb-trans"><p>近期有多位分析師對該公司發表了看法。Needham &amp; Company LLC 將 RxSight 的目標股價從 75.00 美元降至 54.00 美元，並在週二的研究報告中為該公司設定了 “買入” 評級。BTIG Research 將 RxSight 的價格目標從 72.00 美元上調至 73.00 美元，並在 7 月 15 日星期一的研究報告中為該公司設定了 “買入” 評級。Oppenheimer 將 RxSight 的目標股價從 72.00 美元降至 65.00 美元，並在週二的研究報告中為該股設定了 “表現優異” 評級。Stifel Nicolaus 將 RxSight 的目標股價從 70.00 美元降至 65.00 美元，並在週二的研究報告中為該公司設定了 “買入” 評級。最後，富國銀行將 RxSight 的目標股價從 68.00 美元降至 54.00 美元，並在週二的研究報告中為該股設定了 “超重” 評級。根據 MarketBeat 的數據，共有七位分析師對該股票給予買入評級，目前市場普遍看好該公司，預期目標股價為 58.43 美元。</p>
</div><p><strong>Read Our Latest Stock Report on RXST</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 RXST 的最新股票報告</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士的交易</h2>
</div><p>In other RxSight news, Director Julie Andrews sold 15,625 shares of the stock in a transaction on Friday, June 14th. The stock was sold at an average price of $58.00, for a total transaction of $906,250.00. Following the completion of the transaction, the director now directly owns 30,287 shares in the company, valued at $1,756,646. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. In other RxSight news, Director Julie Andrews sold 15,625 shares of the company's stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $58.00, for a total transaction of $906,250.00. Following the sale, the director now directly owns 30,287 shares of the company's stock, valued at $1,756,646. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this link. Also, CFO Shelley B. Thunen sold 10,000 shares of RxSight stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $58.61, for a total transaction of $586,100.00. Following the completion of the transaction, the chief financial officer now owns 13,938 shares of the company's stock, valued at approximately $816,906.18. The disclosure for this sale can be found here. Corporate insiders own 9.36% of the company's stock.</p>
<div class="lb-trans"><p>在其他 RxSight 新聞中，董事朱莉·安德魯斯於 6 月 14 日星期五以每股 58.00 美元的均價出售了 15,625 股股票。交易總額為 906,250.00 美元。交易完成後，該董事在公司中直接持有 30,287 股股票，價值 1,756,646 美元。該交易已在證券交易委員會的一份文件中披露，可通過此超鏈接訪問。此外，RxSight 的另一條消息顯示，首席財務官雪莉·B·圖南於 7 月 1 日星期一以每股 58.61 美元的均價出售了 10,000 股 RxSight 股票。交易總額為 586,100.00 美元。交易完成後，首席財務官現在持有公司 13,938 股股票，價值約 816,906.18 美元。有關此交易的披露可在此處找到。公司內部人士持有公司股份的比例為 9.36%。</p>
</div><h2>About RxSight (Get Free Report)</h2>
<div class="lb-trans"><h2>關於 RxSight（獲得免費報告）</h2>
</div><p>RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.</p>
<div class="lb-trans"><p>RxSight, Inc.是一家商業化階段的醫療器械公司，從事研究、開發、製造和銷售用於白內障手術的可調光人工晶狀體（LAL）在美國和國際市場的使用。公司提供的 RxSight 系統使醫生能夠為白內障手術後的患者定製和增強視力。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than RxSight</li>
<li>What Are Dividend Achievers? An Introduction</li>
<li>Uber's Earnings Beat: Rideshare and Delivery Surge</li>
<li>NYSE Stocks Give Investors a Variety of Quality Options</li>
<li>Hims &amp; Hers Reports Stellar Quarter: Stock Set for a Rally</li>
<li>Technology Stocks Explained: Here's What to Know About Tech</li>
<li>Cloudflare Stock Flares Up on Solid EPS Beat and Raised Guidance</li>
</ul>
<div class="lb-trans"><h2>精選文章</h2>
<ul>
<li>我們喜歡的五隻股票勝過 RxSight</li>
<li>什麼是股息成就者？簡介</li>
<li>Uber 的盈利超預期：共享乘車和外賣激增</li>
<li>紐約證券交易所股票為投資者提供多樣的優質選擇</li>
<li>Hims &amp; Hers 報告季度業績強勁：股價即將上漲</li>
<li>解析科技股：瞭解科技股的相關知識</li>
<li>Cloudflare 股價因業績超預期和業績指引上調而飆升</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlhTVA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=RXST"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由 MarketBeat 的敍事科技和金融數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊的審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ Time is Running Out - June 25th Deadline Approaching! (From Paradigm Press)(Ad)</p>
<div class="lb-trans"><p>→ 時間不多了-6 月 25 日截止日期即將到來！（來自 Paradigm Press）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDEz" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9013&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in RxSight right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資 1,000 美元購買 RxSight？</h2>
</div><p>Before you consider RxSight, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 RxSight 之前，您需要聽到這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RxSight wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂尖和表現最佳的研究分析師以及他們向客户推薦的股票。MarketBeat 已確定了頂級分析師悄悄告訴客户在更廣泛市場注意之前購買的五隻股票...而 RxSight 並不在名單上。</p>
</div><p>While RxSight currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 RxSight 目前在分析師中有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

RxSight（納斯達克代碼：RXST）公佈季度財報，每股收益比預期低 0.09 美元